Skip header and navigation

5 records – page 1 of 1.

2nd-generation HIV surveillance and injecting drug use: uncovering the epidemiological ice-berg.

https://arctichealth.org/en/permalink/ahliterature84543
Source
Int J Public Health. 2007;52(3):166-72
Publication Type
Article
Date
2007
Author
Reintjes Ralf
Wiessing Lucas
Author Affiliation
Department of Public Health, Faculty Life Sciences, Hamburg University of Applied Sciences, Hamburg, Germany. Ralf.Reintjes@rzbd.haw-hamburg.de
Source
Int J Public Health. 2007;52(3):166-72
Date
2007
Language
English
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - epidemiology - prevention & control - therapy
Cost-Benefit Analysis
Europe - epidemiology
HIV Infections - epidemiology - prevention & control - therapy
Hepatitis C - epidemiology
Humans
Norway - epidemiology
Population Surveillance
Prevalence
Risk factors
Risk-Taking
Substance Abuse, Intravenous - epidemiology
Turkey - epidemiology
Abstract
OBJECTIVES: HIV/AIDS surveillance methods are under revision as the diversity of HIV epidemics is becoming more apparent. The so called "2nd generation surveillance (SGS) systems" aim to enhance surveillance by broadening the range of indicators to prevalence, behaviors and correlates, for a better understanding and a more complete and timely awareness of evolving epidemics. METHODS: Concepts of HIV SGS are reviewed with a special focus on injecting drug users, a major at-risk and hard to reach group in Europe, a region with mainly low or concentrated epidemics. RESULTS: The scope of HIV/AIDS surveillance needs to be broadened following principles of SGS. Specifically for IDUs we propose including hepatitis C data as indicator for injecting risk in routine systems like those monitoring sexually transmitted infections and information on knowledge and attitudes as potential major determinants of risk behavior. CONCLUSIONS: The suggested approach should lead to more complete and timely information for public health interventions, however there is a clear need for comparative validation studies to assess the validity, reliability and cost-effectiveness of traditional and enhanced HIV/AIDS surveillance systems.
PubMed ID
17958283 View in PubMed
Less detail

[Acquired immunodeficiency syndrome in Russia].

https://arctichealth.org/en/permalink/ahliterature294740
Source
Ter Arkh. 2016; 88(11):4-11
Publication Type
Journal Article
Author
V V Pokrovsky
Author Affiliation
Central Research Institute of Epidemiology, Federal Service for Supervision of Consumer Rights Protection and Human Welfare, Moscow, Russia.
Source
Ter Arkh. 2016; 88(11):4-11
Language
Russian
Publication Type
Journal Article
Keywords
Acquired Immunodeficiency Syndrome - epidemiology - prevention & control - therapy
Adult
HIV Infections
Humans
Prevalence
Russia - epidemiology
Abstract
In 2015, the infection caused by human immunodeficiency virus (HIV) (HIV infection) dominated among life-threatening infections in Russians: it was first diagnosed in 98,177 Russians and 15,530 citizens of the Russian Federation died from HIV/AIDS, amounting to 45% of all deaths from infectious diseases in Russia. By the mid-2016, there were a total of 1,062,476 identified HIV-positive Russians, of whom 225,992 people died. The estimated number of HIV-infected patients in Russia approximated to 1% of the population, the highest prevalence of HIV being found in the age group of 30-40 years. The most active and expensive measures against HIV/AIDS in Russia are to examine the population for anti-HIV antibodies (29 million screenings per year) and to use in HIV-positive people antiretroviral therapy that was free of charge to more than 200,000 patients, i.e. nearly 25% of the registered Russians living with the HIV-infected. However, treatment coverage and quality are far from the target indicators that the international experts consider needed to reduce HIV prevalence and mortality. A wider program on HIV/AIDS, which includes a number of preventive measures with proven efficiency, as well as a program of promising researches and developments should be introduced in Russia.
? 2015 ?. ????????, ?????????? ??????? ?????????????? ???????? (???) - ???-????????, ?????? ?????????? ????? ????? ????????, ?????????? ????? ???????: ??? ??????? ??????????????? ? 98 177 ???????, ? ?? ???/???? ?????? 15 530 ??????? ?????????? ?????????, 45% ???? ???????, ??????? ?? ???????????? ???????????. ? ???????? 2016 ?. ????? ????? ?????????? ???-?????????? ??????? ????????? 1 062 476, ?? ??????? 225 992 ??????. ????????? ????? ??????? ???-????????? ? ?????? ???????????? ? 1% ?????????, ?????? ?????????? ??????? ???????????? ??? ????????????? ? ?????????? ?????? 30-40 ???. ?????? ????????? ? ?????????????? ????????????? ?? ??????????????? ???/???? ? ?????? ???????? ???????????? ????????? ?? ???????? ? ??? (?????????? 29 ??? ???????????? ? ???) ? ?????????? ???-?????????? ????? ????????????????? ???????, ??????? ? 2015 ?. ????????? ??????????????? ????? 200 ???. ?????????, ?.?. ???????? 25% ??????????????????, ??????? ? ???, ???????. ?????? ????? ???????? ? ??? ???????? ?????? ?? ??????? ???????????, ??????? ????????????? ???????? ??????? ????????????, ????? ????????? ??????????????? ??? ? ????????? ??????????. ????????????? ???????? ? ?????? ????? ??????? ????????? ?? ??????????????? ???/????, ?????????? ??? ???????????????? ??????????? ? ?????????? ??????????????, ? ????? ????????? ????????????? ??????? ???????????? ? ??????????.
????????? ? 2015 ?. ????????, ?????????? ??????? ?????????????? ???????? (???) — ???-????????, ?????? ?????????? ????? ????? ????????, ?????????? ????? ???????: ??? ??????? ??????????????? ? 98 177 ???????, ? ?? ???/???? ?????? 15 530 ??????? ?????????? ?????????, 45% ???? ???????, ??????? ?? ???????????? ???????????. ? ???????? 2016 ?. ????? ????? ?????????? ???-?????????? ??????? ????????? 1 062 476, ?? ??????? 225 992 ??????. ????????? ????? ??????? ???-????????? ? ?????? ???????????? ? 1% ?????????, ?????? ?????????? ??????? ???????????? ??? ????????????? ? ?????????? ?????? 30—40 ???. ?????? ????????? ? ?????????????? ????????????? ?? ??????????????? ???/???? ? ?????? ???????? ???????????? ????????? ?? ???????? ? ??? (?????????? 29 ??? ???????????? ? ???) ? ?????????? ???-?????????? ????? ????????????????? ???????, ??????? ? 2015 ?. ????????? ??????????????? ????? 200 ???. ?????????, ?.?. ???????? 25% ??????????????????, ??????? ? ???, ???????. ?????? ????? ???????? ? ??? ???????? ?????? ?? ??????? ???????????, ??????? ????????????? ???????? ??????? ????????????, ????? ????????? ??????????????? ??? ? ????????? ??????????. ????????????? ???????? ? ?????? ????? ??????? ????????? ?? ??????????????? ???/????, ?????????? ??? ???????????????? ??????????? ? ?????????? ??????????????, ? ????? ????????? ????????????? ??????? ???????????? ? ??????????.
PubMed ID
28005025 View in PubMed
Less detail
Source
Tidsskr Nor Laegeforen. 1997 Nov 30;117(29):4203
Publication Type
Article
Date
Nov-30-1997
Author
P. Aavitsland
Source
Tidsskr Nor Laegeforen. 1997 Nov 30;117(29):4203
Date
Nov-30-1997
Language
Norwegian
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - epidemiology - prevention & control - therapy
Humans
Incidence
Norway - epidemiology
PubMed ID
9441458 View in PubMed
Less detail